AUTHORS
Catherine Nicole Gocho Domingo, MD, Shruti Chaturvedi Jr, MBBS, MS2, Kathryn E. Dane, PharmD, BCPS3, Charlotte M Story, MD4
AFFILIATIONS
1 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
2 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
3 Johns Hopkins Hospital, Baltimore, Maryland, United States
4 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
ABSTRACT
Background
Heparin-induced thrombocytopenia (HIT) is a prothrombotic, immune-mediated adverse drug reaction caused by antibodies against platelet factor 4 (PF4)-heparin complexes. Standard treatment involves immediate discontinuation of heparin and initiation of non-heparin anticoagulation. Intravenous immunoglobulin (IVIG) has emerged as an adjunctive treatment strategy in clinical scenarios where conventional treatment alone may be insufficient or contraindicated. Although IVIG is increasingly incorporated into the management of select patients with HIT, contemporary data describing treatment patterns and clinical outcomes remain limited. We describe a retrospective case series of adults with HIT treated with IVIG, including indications for adjunctive therapy and clinical outcomes.
Methods
We performed a retrospective case series of adult patients with laboratory-confirmed HIT who received IVIG at Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center from 2021-2025. Patients were identified through positive PF4/heparin enzyme-linked immunosorbent assay (ELISA) and/or serotonin release assay (SRA) testing, with diagnosis confirmed by manual chart review. Clinical records were reviewed for demographics, HIT characteristics, laboratory findings, thrombotic complications, IVIG indication and dosing, concomitant therapies, and clinical outcomes including PLT recovery (defined as PLT ≥150 × 10⁹/L on two consecutive measurements), bleeding, recurrent thrombosis, adverse reactions, and disposition.
Results
We identified five patients who received adjunctive IVIG for HIT, including one patient who required IVIG during two separate hospitalizations. Median age was 64 (range, 59-73 years), four patients (80%) were male, median 4Ts score was 5 (range, 5-7), and median anti-PF4 ELISA optical density was 2.85 (range, 1.94-3.34). Median PLT count at IVIG administration was 50×10⁹/L (range, 18-224x10⁹/L) and mean PLT count was 31.6x10⁹/L (range, 18-88x10⁹/L) among patients with active HIT at time of IVIG administration. Most IVIG courses (5/7) consisted of a total dose of 1-2g/kg in divided doses, although lower doses were used in selected patients. Six of seven IVIG courses (86%) were administered in patients with active HIT and pre-existing thrombotic complications.
Among the 5 patients with active HIT-associated thrombocytopenia who received IVIG, four (80%) achieved PLT recovery. One patient with metastatic malignancy and dialysis-dependent renal failure transitioned to hospice before PLT recovery could be achieved. Among those who achieved PLT recovery, the mean time to PLT recovery was 10.5 days (range, 4-19 days). One patient received IVIG after PLT recovery in the setting of necessary heparin re-exposure for urgent cardiac surgery. No in-hospital deaths occurred. Notably, no IVIG-related adverse events were identified, including new thrombosis, bleeding, infusion reactions, hemolysis, or volume overload.
Despite diverse clinical presentations, three recurring, overlapping indications for adjunctive IVIG emerged. First, IVIG was administered for persistent thrombocytopenia despite standard management of HIT (n=3). Second, IVIG was incorporated into perioperative management for patients requiring urgent surgery or planned heparin re-exposure (n=2), including neurosurgical intervention and left ventricular assist device implantation, to facilitate safe operative management while minimizing thrombotic risk, alongside non-heparin anticoagulation and, in selected cases, plasma exchange (n=2). Third, IVIG was used as adjunctive therapy to facilitate more rapid platelet recovery when prompt improvement was clinically important, such as major surgery (n=2). Notably, in all treatment courses, IVIG was administered as an adjunct to therapeutic bivalirudin rather than primary therapy.
Conclusion
This case series characterizes a single center experience using adjunctive IVIG in patients with HIT when standard management alone was considered insufficient due to persistent thrombocytopenia, perioperative management challenges, or planned heparin re-exposure.These findings highlight clinical decision-making and scenarios in which IVIG may be considered. No major safety events occurred in this small cohort, suggesting IVIG may be safe in this patient population. A larger retrospective single-center study is underway to compare outcomes among patients with HIT treated with and without IVIG and better define patient selection.
DISCLOSURES
Catherine Nicole Gocho Domingo, MD: No relevant conflicts of interest to declare.